Perceptive Advisors LLC Bellus Health Inc. Transaction History

Perceptive Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.14 - $8.53 $28.1 Million - $33.6 Million	-3,938,489 Reduced 44.3%	4,952,538 $35.7 Million
Q4 2022 Feb 14, 2023	SELL	$8.22 - $10.76 $11.1 Million - $14.6 Million	-1,356,046 Reduced 13.23%	8,891,027 $73.1 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $42.2 Million - $56.6 Million	4,712,904 Added 85.16%	10,247,073 $108 Million
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $16.8 Million - $26.1 Million	-2,602,461 Reduced 31.98%	5,534,169 $51.1 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $2.73 Million - $3.93 Million	491,396 Added 6.43%	8,136,630 $56 Million
Q4 2021 Feb 14, 2022	BUY	$5.26 - $8.3 $40.2 Million - $63.5 Million	7,645,234 New	7,645,234 $61.5 Million
Q3 2020 Nov 16, 2020	SELL	$2.14 - $12.02 $2.41 Million - $13.5 Million	-1,125,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$8.88 - $11.15 $9.99 Million - $12.5 Million	1,125,000 New	1,125,000 $11.6 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.